Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) partnered with Nanjing Vazyme Biotech (SHA:688105) in a cooperation agreement to set up a biopharmaceutical joint venture, according to a Shanghai bourse filing on Saturday.
The venture will set up production lines that will produce 10 tons of active pharmaceutical ingredients every year.
Sinopep-Allsino will own 51% of the venture, and Vazyme Biotech will hold 49%.
Sinopep-Allsino's shares closed 10% higher, while Vazyme Biotech's shares closed over 5% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。